Genmab (GMAB) is maintaining its 2026 financial guidance published February 17, the company stated with its Q1 report.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab Advances Rina S Into Phase 2 GI Cancer Trial, Raising Long Term Pipeline Hopes
- Genmab Posts Strong Q1 2026 Revenue Growth and Highlights FDA Label Change for EPKINLY
- Genmab price target lowered to $38 from $40 at H.C. Wainwright
- Genmab: Buy Rating Backed by Expanded Petosemtamab-Keytruda Phase III Trial and Blockbuster Late-Stage Pipeline
- Genmab upgraded to Outperform from Neutral at BNP Paribas